Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

18,079 total articles

IPO Plans Falter in 2026 as Volatile Markets and Valuation Pressure Bite

IPO Plans Falter in 2026 as Volatile Markets and Valuation Pressure Bite

A wave of postponements and reduced deal sizes has hit 2026 initial public offerings in the United States as market turbulence, tougher valuation checks and weak peer showings curb the pipeline for new listings. Notable issuers including Clear Street, Agibank and Liftoff Mobile have each taken steps to trim or halt plans while monitoring conditions…

Warner Bros Discovery Turns Down Paramount Skydance’s Latest $30 Offer, Invites Improved Bid

Warner Bros Discovery Turns Down Paramount Skydance’s Latest $30 Offer, Invites Improved Bid

Warner Bros Discovery has declined Paramount Skydance’s revised hostile takeover offer of $30 per share, while allowing the suitor a seven-day window to present a higher proposal. Paramount purportedly floated an informal $31-per-share price that prompted the company to set a deadline of February 23 for a "best and final" bid. Under the terms of Wa…

eToro Posts Q4 Gains, Surpasses Profit Estimates on Multi-Asset Demand

eToro Posts Q4 Gains, Surpasses Profit Estimates on Multi-Asset Demand

eToro reported fourth-quarter adjusted earnings that exceeded analyst expectations, supported by growth across the range of asset classes it offers. The company saw its assets under administration rise year-on-year even as net contribution from crypto and margin-related items declined. Broader market dynamics during the quarter included rising U.S.…

Ocular Therapeutix Shares Slide After SOL-1 Top-Line Results for Axpaxli, Despite Statistically Significant Outcomes

Ocular Therapeutix Shares Slide After SOL-1 Top-Line Results for Axpaxli, Despite Statistically Significant Outcomes

Ocular Therapeutix (OCUL) saw its stock fall 25% after releasing top-line results from the Phase 3 SOL-1 superiority trial of Axpaxli in wet age-related macular degeneration (AMD). The study reached its primary endpoint, with Axpaxli outperforming Regeneron’s Eylea on the percentage of patients maintaining visual acuity at both 36 and 52 weeks. Mar…

Saudi Shares Close Lower as Media, Transport and Tourism Weigh on Tadawul

Saudi Shares Close Lower as Media, Transport and Tourism Weigh on Tadawul

Saudi Arabia's stock market finished Tuesday in negative territory, driven by sector-wide declines in Media & Publishing, Transport and Hotels & Tourism. The Tadawul All Share fell 0.77% at the close, with notable individual gains in tourism, financing and education names offset by sharp drops in mining, information systems and learning stocks. Com…

Berenberg Urges Caution as Valuations Diverge Among European Cable Makers

Berenberg Urges Caution as Valuations Diverge Among European Cable Makers

Berenberg remains positive on the European cable sector, citing structural demand drivers such as data centre expansion, electrification, renewables and grid investment. However, the bank says investors must be selective as valuation gaps widen and medium-term expectations reset, reiterating a Buy on Nexans, downgrading Prysmian to Hold and keeping…

Kyndryl Shares Climb After Form 10-Q Filed; No Restatements Reported

Kyndryl Shares Climb After Form 10-Q Filed; No Restatements Reported

Kyndryl's stock rose 10% after the company filed its Form 10-Q for the quarter ended Dec. 31, 2025, confirming there were no restatements of current or previously reported financial statements. The company also submitted amendments to its 2025 fiscal-year 10-K and two earlier 10-Qs, and disclosed material weaknesses in internal control over financi…

General Mills Cuts Fiscal 2026 Outlook as Consumer Demand Remains Soft

General Mills Cuts Fiscal 2026 Outlook as Consumer Demand Remains Soft

General Mills trimmed its full-year fiscal 2026 guidance, pointing to subdued consumer sentiment and a slower volume recovery than anticipated. The maker of packaged foods now sees organic net sales falling more steeply and expects sharper declines in adjusted operating profit and adjusted diluted EPS, even as it continues to invest behind brand di…

UBS Upgrade Lifts Avolta on Strong Cash Flow and Sharper Capital Focus

UBS Upgrade Lifts Avolta on Strong Cash Flow and Sharper Capital Focus

UBS upgraded Avolta AG from neutral to buy and raised its 12-month price target to CHF65 from CHF48, citing tighter capital discipline, stronger passenger demand outlook and a free cash flow yield the brokerage believes is not yet reflected in the share price. The research note included revised earnings and cash flow forecasts, a suite of scenario …

Ocular Therapeutix Shares Dive After Positive AXPAXLI Phase 3 Readout

Ocular Therapeutix Shares Dive After Positive AXPAXLI Phase 3 Readout

Ocular Therapeutix reported that its AXPAXLI candidate met the primary endpoint in the Phase 3 SOL-1 trial for wet age-related macular degeneration, but the company's shares plunged 35% on the news. The SOL-1 data showed a significant advantage over aflibercept at Week 36; the company plans to discuss a potential NDA submission with the FDA while a…

General Mills Cuts Fiscal 2026 Outlook; Shares Slip on Softer Demand

General Mills Cuts Fiscal 2026 Outlook; Shares Slip on Softer Demand

General Mills shares fell 3.6% on Tuesday morning after the Minneapolis-based packaged-food company downgraded its fiscal 2026 outlook. The firm now expects organic net sales to decline 1.5% to 2% and has widened the hit to adjusted operating profit and adjusted diluted earnings per share to a 16% to 20% fall in constant currency. Management attrib…